Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Aim(s): To evaluate the disease control rate (DCR) at first radiologic assessment (8-12 week) defined as the proportion of best radiological response achieved in pts with CR, PR or SD, as a measure of antitumor effect of EV in pWDNETs naïve pts or progressing after CT and/or SSAs.
Materials and methods: We retrospectively analyzed 32 pWDNETs pts treated with EV, between 2009 to 2012 in our Institution.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Pusceddu
, De Braud F
, Milione M
, Mazzaferro V
, Damato A
, Coppa J
, Seregni E
, Dautilio E
, Del Conte G
, Marchianò A
, Buzzoni R
To read results and conclusion, please login ...
Further abstracts you may be interested in